Visx claims US first for CustomVue eye laser:
This article was originally published in Clinica
Visx has received FDA approval for what it claims to be the first US-approved wavefront-guided laser treatment for hyperopia. The CustomVue laser vision correction procedure, which was also approved for treating astigmatism, uses the firm's WaveScan technology, a diagnostic system that captures a comprehensive "fingerprint" of each eye and generates an individualised treatment for each CustomVue procedure. "We believe this further advancement of laser vision correction technology will enhance our market leadership position, drive CustomVue conversions, and increase future revenue and profit opportunities," said Liz Davila, the Santa Clara, California firm's chairman and CEO.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.